644 related articles for article (PubMed ID: 32227567)
1. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine.
Januska MN; Marx L; Walker PA; Berdella MN; Langfelder-Schwind E
J Genet Couns; 2020 Aug; 29(4):607-615. PubMed ID: 32227567
[TBL] [Abstract][Full Text] [Related]
2. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
3. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
4. Detection of disease-causing CFTR variants in state newborn screening programs.
McGarry ME; Ren CL; Wu R; Farrell PM; McColley SA
Pediatr Pulmonol; 2023 Feb; 58(2):465-474. PubMed ID: 36237137
[TBL] [Abstract][Full Text] [Related]
5. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
[TBL] [Abstract][Full Text] [Related]
6. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
7. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
8. Who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies.
Desai M; Hine C; Whitehouse JL; Brownlee K; Charman SC; Nagakumar P
Respir Med; 2022 Aug; 199():106878. PubMed ID: 35633605
[TBL] [Abstract][Full Text] [Related]
9. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
Donaldson SH; Pilewski JM; Griese M; Cooke J; Viswanathan L; Tullis E; Davies JC; Lekstrom-Himes JA; Wang LT;
Am J Respir Crit Care Med; 2018 Jan; 197(2):214-224. PubMed ID: 28930490
[TBL] [Abstract][Full Text] [Related]
10. Variation in cystic fibrosis newborn screening algorithms in the United States.
Rehani MR; Marcus MS; Harris AB; Farrell PM; Ren CL
Pediatr Pulmonol; 2023 Mar; 58(3):927-933. PubMed ID: 36507555
[TBL] [Abstract][Full Text] [Related]
11. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
12. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY
Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331
[TBL] [Abstract][Full Text] [Related]
14. Current Status of Genetic Diagnosis Laboratories and Frequency of Genetic Variants Associated with Cystic Fibrosis through a Newborn-Screening Program in Turkey.
Bozdogan ST; Mujde C; Boga I; Sonmezler O; Hanta A; Rencuzogullari C; Ozcan D; Altintas DU; Bisgin A
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33572515
[TBL] [Abstract][Full Text] [Related]
15. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years.
Skov M; Baekvad-Hansen M; Hougaard DM; Skogstrand K; Lund AM; Pressler T; Olesen HV; Duno M
Pediatr Pulmonol; 2020 Feb; 55(2):549-555. PubMed ID: 31682332
[TBL] [Abstract][Full Text] [Related]
16. CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare
Lefferts JW; Bierlaagh MC; Kroes S; Nieuwenhuijze NDA; Sonneveld van Kooten HN; Niemöller PJ; Verburg TF; Janssens HM; Muilwijk D; van Beuningen SFB; van der Ent CK; Beekman JM
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833986
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
18. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
Rowe SM; Daines C; Ringshausen FC; Kerem E; Wilson J; Tullis E; Nair N; Simard C; Han L; Ingenito EP; McKee C; Lekstrom-Himes J; Davies JC
N Engl J Med; 2017 Nov; 377(21):2024-2035. PubMed ID: 29099333
[TBL] [Abstract][Full Text] [Related]
19. Elexacaftor/Ivacaftor/Tezacaftor: First Approval.
Hoy SM
Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874
[TBL] [Abstract][Full Text] [Related]
20. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
